Age, gender and BCG vaccination status as risk factors for Leprosy in endemic areas of northern Brazil.

Luana Nepomuceno Gondim Costa Lima (✉ luanalima@iec.gov.br)

Universidade do Estado do Para <https://orcid.org/0000-0002-0642-4248>

Jasna Letícia Pinto Paz

Universidade do Estado do Para Centro de Ciencias Biologicas e da Saude

Maria do Perpétuo Socorro Corrêa Amador Silvestre

Instituto Evandro Chagas

Letícia Siqueira Moura

Universidade do Estado do Para Centro de Ciencias Biologicas e da Saude

Ismari Perini Furlaneto

Centro Universitario do Estado do Para

Karla Valéria Batista Lima

Instituto Evandro Chagas

Research

Keywords: Leprosy, Mycobacterium leprae, Epidemiology, BCG

Posted Date: August 12th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-55511/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background In 2018, 208.619 new cases of the leprosy were reported to the World Health Organization (WHO). Of these, 30.957 occurred in the Americas region and 28.660 (92.6% of the total in the Americas) were reported in Brazil. This study aimed to show the reality of the profile of a population in an endemic leprosy area in northern Brazil in relation to age, gender and BCG (bacilo Calmette-Guérin) vaccination status, through the collection of data in the field with evaluation of the study individuals, recruited by spontaneous demand.

Methods 405 individuals participated in the study, being 100 multibacillary, 57 paucibacillary and 248 healthy contacts.

Results A relationship was observed between the occurrence of the disease, as well as the multibacillary form with the largest age group. The male gender was associated with leprosy per se, with the multibacillary form and was the largest representative of the group that was not vaccinated once.

Conclusion BCG vaccination was effective both in protecting against leprosy per se and in the multibacillary form. These results are limited by sample size, may not be conclusive and will need further confirmation in a larger cohort.

Introduction

Leprosy is an infectious, transmissible and chronic disease, which still persists as a public health problem in Brazil. Its etiologic agent is *Mycobacterium leprae*, a bacillus that mainly affects peripheral nerves, eyes and skin. The disease affects people of any gender or age group, and may have a slow and progressive evolution and, when left untreated, can cause deformities and physical disabilities, often irreversible (1).

In 2018, 208.619 new cases of the disease were reported to the World Health Organization (WHO). Of these, 30.957 occurred in the Americas region and 28.660 (92.6% of the total in the Americas) were reported in Brazil. Between 2014 and 2018, 140.578 new leprosy cases were diagnosed in Brazil, among which 77.544 cases occurred in males (55,2%). In the same period, a predominance of this gender was observed in most age groups. The largest number of cases was identified in individuals between 50 and 59 years old, totaling 26.245. In 2019, Brazil diagnosed 23.612 new leprosy cases, 78,2% were classified as multibacillary. Of the new cases, 1.319 (5,6%) were in children under 15 years old. Given this scenario, Brazil is classified as a country with a high burden for the disease, ranking second in the list of countries with the highest number of cases in the world, behind only India (2).

In 1991, the Brazilian Ministry of Health officially recommended that home contacts of leprosy patients be revaccinated with BCG (bacilo Calmette-Guérin) to increase the effectiveness of the first dose administered to newborns as a prophylactic vaccine for tuberculosis. The justification for using BCG as a leprosy vaccine rests on the knowledge that *M. leprosy* and *M. bovis* (BCG) share many antigens with a

high degree of homology. Contacts without a BCG scar or with just one are vaccinated, and with two scars they are not vaccinated. And it is currently established that BCG provides some protection against leprosy (3–5).

Currently, the fight against leprosy is a priority for the Ministry of Health of Brazil, and the epidemiological knowledge of the disease in the region and the vaccination status of individuals with BCG are an important tool to outline action strategies for the early detection of cases, in order to prevent physical disabilities and promote a break in the transmission chain. Thus, this study aimed to show the reality of the profile of a population in an endemic leprosy area in northern Brazil in relation to age, gender and BCG vaccination status, through the collection of data in the field with evaluation of the study individuals, recruited by spontaneous demand.

Methodology

Sampling and data collection

The study included individuals from four leprosy endemic municipalities in the State of Pará, in northern Brazil: Rondon do Pará, Curianópolis, Goianésia and Redenção. Participants were divided into two groups of patients and contacts, and recruitment was carried out on spontaneous demand at the municipal health centers.

The group of patients was composed of individuals with a clinical diagnosis of leprosy, undergoing treatment from three months to five months, who at the time of diagnosis were classified according to the Ministry of Health of Brazil into paucibacillary (PB) or multibacillary (MB) (2, 6). The contact group consisted of individuals who lived with leprosy patients and did not have clinical symptoms of leprosy. Thus, 405 individuals participated in the study, being 100 multibacillary, 57 paucibacillary and 248 healthy contacts.

Data on age, gender and BCG vaccination were collected using the participant's identity document and vaccination card.

All participants provided written informed consent and the study was approved by the municipal health authorities and the Research Ethics Committee of the Evandro Chagas Institute (Ministry of Health) (CAAE 48723115.1.0000.0019).

Statistic

The proportions observed within each studied group were analyzed with the aid of the GraphPad Prism version 8.00, using the G, Chi-square and Fisher's Exact tests to verify the association between variables displayed in 2×2 table. The Odds Ratio association measure was used to assess the association between exposure and the outcomes of interest. Values of $p \leq 0.05$ were considered significant.

Results

Regarding the age group, there was a significantly higher frequency of individuals aged 32 years or older among patients and individuals aged up to 31 years between contacts ($p < 0.0001$). In addition, all age groups from 16 years of age were associated with greater chances of developing leprosy compared to children and adolescents aged 0 to 15 years (Table 1).

Considering only the patients, there was a significantly higher frequency of individuals aged over 46 years among the MB and, among the PB, there was a predominance of individuals aged between 32 and 46 years (54,0% and 50,9%, respectively, $p = 0,0210$). The chance of presenting as MB or PB in the 0 to 15, 16 to 31 and 32 to 46 age groups was statistically similar, and being over 46 years old increased the chance of presenting the MB form three times (OR = 3.375; 95% CI = 0.718–15.280) (Table 1).

With regard to gender, more women were observed between contacts and more men among patients (66,5% and 51,0%, respectively, $p = 0,0006$; Table 1) and being male was associated with doubling the chance of presenting leprosy (OR = 2,065; 95% CI = 1,369–3,073). Considering the disease classification, there was a higher frequency of male patients among MB (58,0%, $p = 0,0212$), and it was observed that being of this gender was related to an increase of approximately 2,1 times the chance of manifesting the MB form of leprosy (OR = 2,197; 95% CI = 0,121–4,245).

With regard to the total doses of BCG vaccine received, there was a significantly higher frequency of contacts among those who received 1 dose of the vaccine and a higher frequency of patients among those who were never vaccinated (58,5% and 43.9%, respectively, $p < 0.0001$; Table 1). Among MB patients, there was a higher proportion of individuals who never received BCG (52,0%) when compared to PB ($p = 0,0183$; Table 1).

Individuals who received one or no dose of the vaccine were significantly more likely to develop leprosy when compared to those who received two or more doses, and the group that did not receive any dose of the vaccine had an 8,4-fold increased chance (OR = 8,431, 95% CI = 4,016–17,260; Table 1). Considering the chance of being multibacillary, this was significantly higher among patients who were never immunized with BCG when compared to the chance of this event among those who took 2 or more doses (OR = 4,200, 95% CI = 1,180 – 13,740; Table 1). Considering the gender and vaccination status of the participants, a significant association was found between the absence of immunization and the male sex and between the female sex and the receipt of 2 or more doses of BCG ($p < 0,0001$; Table 1).

Table 1
Characterization of groups regarding age, gender and doses of BCG vaccine.

	Paciente	Contato	OR (IC 95%)*	p-valor	MB	PB	OR (IC 95%)*	p-valor**
Faixa etária								
0 15	06 (3.8%)	52 (21.0%)	1 (-)	< 0.0001 [†]	3 (3.0%)	3 (5.3%)	1 (-)	0.0210 [†]
16 31	19 (12.1%)	57 (23.0%)	2.889 (1.070–7.631 [†])		10 (10.0%)	9 (15.8%)	1.111 (0.214–5.726)	
32 46	62 (39.5%)	70 (28.2%)	7.676 (3.244–17.980 [†])		33 (33.0%)	29 (50.9%)	1.138 (0.249–5.164)	
> 46	70 (44.6%)	69 (27.8%)	8.792 (3.514–20.480 [†])		54 (54.0%)	16 (28.0%)	3.375 (0.718–15.280)	
Total	157 (100%)	248 (100%)			100 (100%)	57 (100%)		
Gender								
Female	77 (49.0%)	165 (66.5%)	1 (-)	0.0006 [†]	42 (42.0%)	35 (61.4%)	1 (-)	0.0212 [†]
Male	80 (51.0%)	83 (33.5%)	2.065 (1.369–3.073 [†])		58 (58.0%)	22 (38.6%)	2.197 (1.121–4.245 [†])	
Total	157	248			100	57		
BCG								
0	68 (43.9%)	41 (16.7%)	8.431 (4.016–17.260 [†])	< 0.0001 [†]	51 (52.0%)	17 (29.8%)	4.200 (1.180–13.740 [†])	0.0183 [†]
1	75 (48.4%)	144 (58.5%)	2.648 (1.345–5.052 [†])		42 (42.9%)	33 (57.9%)	1.782 (0.538–5.519)	
≥ 2	12 (7.7%)	61 (24.8%)	1 (-)		5 (5.1%)	7 (12.3%)	1 (-)	
Total	155	246			98	57		

MB: multibacillary. PB: paucibacillary. BCG: dose of bacillus Calmette-Guérin vaccine. * Odds Ratio, with a 95% confidence interval. ** Chi-square or G-test of independence (Chi-square residue analysis), as needed. †Statistically significant.

Discussion

The age group above 46 years old prevalent in the group of patients and with 8,7 times greater chances of developing the disease (OR = 8,792) corroborates with previous studies, which show that it is common in Brazil that leprosy has its highest concentration rates among the older age groups (7). The long bacillus incubation period, the lack of diagnosis and / or late diagnosis can be influencing factors on the high number of older people with the disease (8).

Likewise, the multibacillary manifestation in this study stood out in individuals over 46 years old, in line with the research by Nobre et al. (2017), who sought to identify groups at higher risk for the multibacillary form of leprosy in Brazil, in which they describe that more than half of the Brazilian states have the highest numbers of multibacillaries as age increases. The authors associated this relationship of multibacillary activity with older age groups with the hypothesis that leprosy transmission is decreasing and that these cases reflect a transmission that occurred a while ago and not recently, even because *M. leprae* has a long incubation period (9).

Silva et al. (2018) analyzed the new cases reported from a city in the state of Maranhão (Northeast of Brazil) in the period between 2003 and 2015 and observed that most individuals aged between 50 and 59 years old (59.2%) and, mostly, over 60 years (72.3%) were within the MB classification. The authors proposed as a possible explanation for the high number of sick people at older ages, in addition to the incubation period, the delay in diagnosing these patients, a factor that even keeps them as active sources of infection transmission for long periods of time. This common delay in the diagnosis of leprosy in developing countries was observed in an epidemiological and clinical study with elderly people over 60 years of age, in southern Brazil, in which almost 40% of the patients were in grade II disability, which is a classic late diagnosis feature (10, 11).

In the population of the present study, the contact group was predominantly female, while in the patient group and in the multibacillary group there was a male predominance ($p < 0,05$). Likewise, the chances of developing the disease were 2 times greater for males (OR = 2,065), as well as the chances of developing the multibacillary form were 2 times greater for this gender (OR = 2,197). The relationship found by this research between the male sex and the occurrence of leprosy and, specifically, the development of the MB form of the disease, is also observed by research conducted in northeastern Brazil (7). This relationship raises the social issues surrounding men's health, such as the image of virility and incompatibility of the working hours of health units with the free time of work for these individuals, but it may also be influenced by physiological differences between men and women, because testosterone has immunosuppressive activity in both humoral and cellular responses, while estrogen stimulates the production of TNF α , an important cytokine of the Th1 cellular response. Thus, men and women can be equally exposed to the bacillus, with a higher proportion of men among the cases, due to the men having some susceptibility to develop the disease after being infected (12–15).

Another explanation may be due to a greater exposure of men to the environment compared to women, since men are more inserted in professions that come into contact with soil, water and animals. A study

carried out in Ceará demonstrated that the fact that the individual is male increased the chances of having *M. leprae* DNA in the nose by 6,2 times, which may reflect a greater probability of sex in acquiring the disease (16). In a cohort study by Bakker et al. (2006), it was shown that males are twice as likely to develop leprosy as compared to women (17).

Despite the non-specificity of the bacillus Calmette-Guérin (BCG) vaccine for *M. leprae*, it is approximately 50% effective in protecting against leprosy (3). Brazil, together with Colombia, Peru and Australia, makes up the list of a few countries that use the application of a second dose of BCG vaccine in contacts of new cases of leprosy as a national prophylactic measure. Although not recommended by the World Health Organization (WHO), the application of this vaccination specifically for leprosy prophylaxis is recognized by the WHO for its significant contribution to the decline in the incidence of the disease (5, 18). The BCG vaccine induces the activation of T-cell clones that recognize specific *M. leprae* epitopes, providing a protective effect against disease progression, including leading to negative PGL-I serological tests that were previously positive (4, 19).

In the present study, 83,33% of healthy household contacts of patients were vaccinated at least once. As for the patients, almost half did not receive any dose of the vaccine (Table 1). The group of individuals who did not take any dose of the vaccine was 8.4 times more likely to develop leprosy (OR = 8,431). Studies point out that the second BCG vaccination increases protection against the disease, reaching a 95% decrease in the relative risk with the application of the second dose (18, 20). Among the patients participating in the present study, only 7,1% had received two doses of the vaccine.

In addition, observing the general vaccination situation of the individuals in the study, there is a divergence by gender. The greater number of female individuals vaccinated in relation to the male sex corroborates the idea that, in general, women are more willing to take care of their health than men (13). A similar result was observed in a survey conducted in the Southeast Brazil, in which the percentage of men who did not receive doses of the vaccine was higher than the percentage of women (21).

Thus, BCG vaccination seems to be an indispensable component of any program that aims to control or eradicate leprosy, because, despite important advances in the study of the molecular biology of *M. leprae*, specific vaccines against leprosy are still at an early stage initial development and evaluation. Although both BCG vaccination and treatment with the index case reduce the risk of contacts contracting leprosy, the changes in the immune response induced by these two measures, which could explain the resulting protective effect, still need to be investigated in detail. Thus, in view of the complex current difficulties encountered in eradicating this disease, we continue to need urgent measures to reveal the hidden side of the leprosy “epidemiological iceberg” in order to reduce its morbidity and the physical disabilities resulting from this disease.

Conclusion

A relationship was observed between the occurrence of the disease, as well as the multibacillary form with the largest age group. The male gender was associated with leprosy per se, with the multibacillary

form and was the largest representative of the group that was not vaccinated once. BCG vaccination was effective both in protecting against leprosy per se and in the multibacillary form. These results are limited by sample size, may not be conclusive and will need further confirmation in a larger cohort.

Abbreviations

BCG
bacilo Calmette-Guérin
WHO
World Health Organization
PB
paucibacillary
MB
multibacillary

Declarations

Ethics approval and consent to participate

All participants provided written informed consent and the study was approved by the municipal health authorities and the Research Ethics Committee of the Evandro Chagas Institute (Ministry of Health) with the committee's reference number: 48723115.1.0000.0019.

Consent to publication

Not applicable

Availability of data and material

The data supporting findings can be found with the corresponding author.

Competing interests

There is not financial and non-financial competing interests.

Funding

This research was funded by Ministry of Health of Brazil, CAPES: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior and CNPq: Conselho Nacional de Desenvolvimento Científico e Tecnológico. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Author contributions

- Conceptualization: Luana Nepomuceno Gondim Costa Lima
- Methodology: Luana Nepomuceno Gondim Costa Lima
- Validation: Jasna Letícia Pinto Paz, Letícia Siqueira Moura
- Formal analysis: Ismari Perini Furlaneto, Jasna Letícia Pinto Paz
- Investigation: Luana Nepomuceno Gondim Costa Lima, Jasna Letícia Pinto Paz, Letícia Siqueira Moura
- Resources: Luana Nepomuceno Gondim Costa Lima, Jasna Letícia Pinto Paz
- Data curation: Luana Nepomuceno Gondim Costa Lima, Jasna Letícia Pinto Paz, Letícia Siqueira Moura, Maria do Perpétuo Socorro Corrêa Amador Silvestre
- Writing—original draft preparation: Jasna Letícia Pinto Paz
- Writing—review and editing: Luana Nepomuceno Gondim Costa Lima, Maria do Perpétuo Socorro Corrêa Amador Silvestre, Karla Valéria Batista Lima
- Visualization: Luana Nepomuceno Gondim Costa Lima, Maria do Perpétuo Socorro Corrêa Amador Silvestre, Karla Valéria Batista Lima
- Supervision: Luana Nepomuceno Gondim Costa Lima
- Project administration: Luana Nepomuceno Gondim Costa Lima
- Funding acquisition: Luana Nepomuceno Gondim Costa Lima, Maria do Perpétuo Socorro Corrêa Amador Silvestre, Karla Valéria Batista Lima

Acknowledgements

Not applicable

References

1. dos Santos EC, Machado RLD, Paz JL, Silvestre M do PSCA, Lima KVB, Lima LNGC. Study of TNF- α , IFN- γ , TGF- β , IL-6, and IL-10 gene polymorphism in individuals from the leprosy endemic area in the Brazilian Amazon. Meta Gene [Internet]. 2020;25(May):100740. Available from: <https://doi.org/10.1016/j.mgene.2020.100740>

2. Ministério da Saúde Secretaria de Vigilância em Saúde. Boletim Epidemiológico. 2020.
3. Düppre NC, Camacho LAB, da Cunha SS, Struchiner CJ, Sales AM, Nery JAC, et al. Effectiveness of BCG vaccination among leprosy contacts: a cohort study. *Trans R Soc Trop Med Hyg*. 2008 Jul;102(7):631–8.
4. de Carvalho FM, Rodrigues LS, Duppre NC, Alvim IMP, Ribeiro-Alves M, Pinheiro RO, et al. Interruption of persistent exposure to leprosy combined or not with recent BCG vaccination enhances the response to *Mycobacterium leprae* specific antigens. *PLoS Negl Trop Dis*. 2017;11(5):1–16.
5. WHO/UNICEF. Report on BCG vaccine use for protection against mycobacterial infections including tuberculosis, leprosy, and other nontuberculous mycobacteria (NTM) infections. 2017;1–77.
6. Silvestre M do PSA, Lima MF de, Pereira AGP, Bernardo AR, Diniz RL, Ribeiro PPF, et al. Sensitivity of a Rapid Mix Test with Combined Synthetic Antigens Derived from *Mycobacterium Leprae* PGL-1 for Diagnosis and Surveillance of Leprosy. *Open J Immunol*. 2020;10(01):1–9.
7. Serra MAA de O, Santos C da S, Lima Neto PM, Oliveira KGZ, Oliveira FJF de, Gordon AS de A, et al. Factors Associated with Multibacillary Leprosy in a Priority Region for Disease Control in Northeastern Brazil: A Retrospective Observational Study. *J Trop Med*. 2019 Feb;2019:1–7.
8. Shumet T, Demissie M, Bekele Y. Prevalence of Disability and Associated Factors among Registered Leprosy Patients in All Africa Tb and Leprosy Rehabilitation and Training Centre (ALERT), Addis Ababa, Ethiopia. *Ethiop J Health Sci*. 2015 Oct;25(4):313–20.
9. Nobre ML, Illarramendi X, Dupnik KM, Hacker M de A, Nery JA da C, Jerônimo SMB, et al. Multibacillary leprosy by population groups in Brazil: Lessons from an observational study. *PLoS Negl Trop Dis*. 2017;11(2):e0005364.
10. Diniz LM, Maciel LB. Leprosy: clinical and epidemiological study in patients above 60 years in Espírito Santo State - Brazil. *An Bras Dermatol*. 2018 Dec;93(6):824–8.
11. Silva AR da, Lima Neto PM, Santos LH dos, Lima RJCP, Tauil PL, Gonçalves E da G do R. Factors associated with leprosy in a municipality of the Pre-Amazon region, state of Maranhão, Brazil. *Rev Soc Bras Med Trop*. 2018 Dec;51(6):789–94.
12. Guerra-Silveira F, Abad-Franch F. Sex bias in infectious disease epidemiology: patterns and processes. Nishiura H, editor. *PLoS One*. 2013 Apr;8(4):e62390.
13. Coelho EBS, Schwarz E, Bolsoni CC, Conceição TB. Política Nacional de Atenção Integral à Saúde do Homem UFSC 2018. 2018.
14. Brunelleschi S. Immune response and auto-immune diseases: gender does matter and makes the difference. *Ital J Gender-Specific Med* [Internet]. 2016;2(1):5–14. Available from: http://www.gendermedjournal.it/r.php?v=2288&a=24604&l=326744&f=allegati/02288_2016_01/fulltext/05-14_Brunelleschi.pdf
15. Mukhopadhyay D, Mukherjee S, Ghosh S, Roy S, Saha B, Das NK, et al. A male preponderance in patients with Indian post kala-azar dermal leishmaniasis is associated with increased circulating levels of testosterone. *Int J Dermatol*. 2016;55(5):e250–5.

16. Lima LNGC, Frota CC, Mota RMS, Almeida RLF, Pontes MA de A, Gonçalves H de S, et al. Widespread nasal carriage of *Mycobacterium leprae* among a healthy population in a hyperendemic region of northeastern Brazil. *Mem Inst Oswaldo Cruz*. 2015;110(7):898.
17. Bakker MI, Hatta M, Kwenang A, Van Mosseveld P, Faber WR, Klatser PR, et al. Risk factors for developing leprosy—a population-based cohort study in Indonesia. *Lepr Rev*. 2006 Mar;77(1):48–61.
18. Gillini L, Cooreman E, Wood T, Rao Pemmaraju V, Saunderson P. Global practices in regard to implementation of preventive measures for leprosy. 2017;
19. Limeira OM, Gomes CM, Moraes OO De, Cesetti MV, Alvarez RRA. Busca ativa por casos de hanseníase no centro-oeste do Brasil: Avaliação sorológica dos contatos domiciliares assintomáticos antes e após a profilaxia com *Bacillus Calmette-Guérin*. *Rev Inst Med Trop Sao Paulo*. 2013;55(3):173–7.
20. Araujo S, Rezende MMF, Sousa DCR de, Rosa MR, Santos DC dos, Goulart LR, et al. Risk-benefit assessment of *Bacillus Calmette-Guérin* vaccination, anti-phenolic glycolipid I serology, and Mitsuda test response: 10-year follow-up of household contacts of leprosy patients. *Rev Soc Bras Med Trop*. 2015 Dec;48(6):739–45.
21. Rabite Garcia I. Análise Da Vacinação Bcg Segundo a Classificação Operacional E Gênero Nos Casos Novos De Hanseníase No Município De Ubá/Mg, De 2000 a 2016. 2018;36. Available from: http://www.locus.ufv.br/bitstream/handle/123456789/20953/texto_completo.pdf?sequence=1